Clinical trials: Clinical Trial, Phase I
Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors
A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
AL2846 is a multi-target receptor tyrosine kinase inhibitor. The purpose of this study is to evaluate the safety and efficacy of AL2846 capsules in Chinese patients with type I neurofibromatosis (NF1) (neurofibromas and malignant…
- Trial name
- NCT05011019
- Testing
- AL2846 capsules
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Renal Insufficiency
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function
The main objective of this study was to assess the effect of normal and impaired renal function on the safety, pharmacokinetics, and pharmacodynamics of linagliptin following oral administration of 5 mg daily for 7 days (Groups 1…
- Trial name
- NCT02191228
- Testing
- Linagliptin - single dose, Linagliptin - Multiple dose
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Respiratory Syncytial Virus Infections
Safety Study of Oral BTA9881 to Treat RSV Infection
This is a placebo-controlled, double-blind, randomised, single dose escalation Phase I clinical trial to determine the safety and tolerability of BTA9881 administered orally to healthy subjects
- Trial name
- NCT00504907
- Testing
- BTA9881
- Where
- Australia
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Biota Scientific Management Pty Ltd
Sarcoma, Kaposi, HIV Infections
A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
- Trial name
- NCT00002136
- Testing
- Tecogalan sodium
- Where
- United States
- Sponsor
- Daiichi Pharmaceuticals
Advanced Cancer, Advanced Solid Tumor
Oral Administration of STC-15 in Subjects With Advanced Malignancies
This Phase 1, multi-center, open-label, first-in-human study evaluates multiple ascending daily oral doses of STC-15 in Q3W treatment cycles in a 3+3 cohort design with dose levels determined by a modified Fibonacci algorithm.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Cancer
- Trial name
- NCT05584111
- Testing
- STC-15
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- STORM Therapeutics LTD
Charcot-Marie-Tooth Disease, Type IA
Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A
Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients with Charcot-Marie-Tooth disease (CMT) type 1A
- Trial name
- NCT05333406
- Testing
- EN001
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- ENCell
Hypercholesterolemia, Healthy Volunteers
A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants
This is a single-center, randomized, double-blind, placebo-controlled, single HST101 SC dose cohort study to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Chinese Participants with Elevated…
- Conditions
- Hypercholesterolemia, Healthy Volunteers, LDL-Cholesterol
- Trial name
- NCT06504043
- Testing
- HST101
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hasten Biopharmaceutical Co., Ltd.
CD123+ Acute Myeloid Leukemia
Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression
The goal of this Phase 1 clinical trial is to understand whether a new experimental treatment, called ORM-1153, will be a safe and possibly effective treatment option for participants with blood cancers such as Acute Myeloid…
- Trial name
- NCT07809906
- Testing
- ORM-1153
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Orum Therapeutics USA, Inc.
Gastrointestinal Stromal Tumors (GIST), Other Relapsed or Refractory Solid Tumors
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered…
- Trial name
- NCT02508532
- Testing
- Avapritinib
- Where
- 19 sites in United States, Belgium and 8 more
- Volunteers
- 250 people
- Sponsor
- Blueprint Medicines Corporation
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV).
- Trial name
- NCT06319963
- Testing
- Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Theravectys S.A.
Hepatic Fibrosis
QTc Assessment in a Single-Dose Study of Hydronidone Capsules
This study was designed with three dose cohorts (A1-A3): a 90 mg cohort, a 270 mg cohort, and a 540 mg cohort. Each cohort enrolled 16 healthy Chinese participants, with 12 receiving the investigational product Hydronidone…
- Trial name
- NCT07263152
- Testing
- Hydronidone
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Healthy Subjects (HS)
Evaluation of 627 in Healthy Adult Subjects
This is a randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose phase I clinical study to evaluate the safety, tolerability, PK and immunogenicity of SSGJ-627 in healthy adult subjects…
- Trial name
- NCT07065136
- Testing
- 627
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Advanced Retinitis Pigmentosa
AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa
All participants in phase 1 and phase 2a had hand motion visual acuity or worse. If efficacy was demonstrated from phase 1, better vision subjects could be enrolled; however, efficacy was not demonstrated.
- Trial name
- NCT02556736
- Testing
- AGN-151597
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- AbbVie
Breast Cancer, Solid Tumor
A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
This study is an open, multicenter, increasing dose and dose extension nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics and preliminary efficacy of BL-B16D1 in patients…
- Trial name
- NCT06493864
- Testing
- BL-B16D1
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Healthy
This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body
Primary objective mass balance, excretion pathways and metabolism following a single oral dose of [14C]BI 1467335 given to healthy male subjects (a selected number of subjects will be treated with [14C]BI 1467335 after a…
- Trial name
- NCT03382509
- Testing
- [14C]BI 1467335, BI 1467335
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hypertension
A Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers
The purpose of this study is to evaluate pharmacokinetic interactions and safety between fimasartan and linagliptin in healthy male volunteers.
- Trial name
- NCT03250052
- Testing
- (fimasartan or linagliptin) x 7days, (fimasartan and linagliptin) x 7days
- Where
- South Korea
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Osteoarthritis, Knee
Clinical Trial of YY1201 for Treatment of Osteoarthritis of the Knee
This is a multicenter, randomized, double-blinded, parallel, placebo-controlled, phase I/IIa clinical trial of YY1201 for treatment of osteoarthritis of the knee.
- Trial name
- NCT02554552
- Testing
- YY1201 2ml, YY1201 3ml
- Where
- South Korea
- Volunteers
- healthy volunteers welcome
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Head and Neck Cancer, Oropharynx Cancer
Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
The purpose of this study is to evaluate the safety of adding the investigational drug Motexafin Gadolinium to the standard treatment of radiation therapy and chemotherapy with drugs called 5-FU and cisplatin in patients with…
- Conditions
- Head and Neck Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer
- Trial name
- NCT00080028
- Testing
- Motexafin Gadolinium Injection
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pharmacyclics LLC.
Leukocyte Adhesion Deficiency
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)
This Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) is a continuation of a Phase 1/2 clinical study to evaluate the safety and efficacy of the infusion of autologous hematopoietic stem…
- Trial name
- NCT06282432
- Where
- 3 sites in United States, Spain and 1 more
- Volunteers
- 9 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Bladder Cancer
Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder
The primary purpose of this study is to evaluate the response rate of this treatment (Mw) in patients with BCG refractory superficial transitional cell carcinoma.
- Trial name
- STCC (NCT00694798)
- Testing
- Mycobacterium w
- Where
- 17 sites in India
- Volunteers
- 22 people
- Sponsor
- Cadila Pharnmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.